Stock Events

Stock Events

Search...

CureVac N.V.

$2.83

302

+$0.06+1.99% Monday 15:25

Statistics

Day High

2.89

Day Low

2.73

52W High

19.73

52W Low

5.85

Volume

3,702.48

Avg. Volume

3,953

Mkt Cap

-

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

14NovExpected

Q1 2024

Q2 2024

Next

-0.34

0.29

0.93

1.57

Expected EPS

1.56622801456

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A9E.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

BioNTech SE is a direct competitor in the mRNA technology space, focusing on developing vaccines and therapeutics, similar to CureVac's core business.

Moderna, Inc. is a leader in mRNA therapeutics and vaccines, directly competing with CureVac in the COVID-19 vaccine market and other therapeutic areas.

Pfizer Inc., in collaboration with BioNTech, competes in the mRNA vaccine market, particularly with their COVID-19 vaccine, which is in direct competition with CureVac's development.

Novavax, Inc. competes in the vaccine space, particularly with its protein-based COVID-19 vaccine, offering an alternative to mRNA vaccines like those developed by CureVac.

Johnson & Johnson

Johnson & Johnson competes in the vaccine market with its viral vector COVID-19 vaccine, offering an alternative approach to CureVac's mRNA technology.

AstraZeneca PLC competes with its viral vector COVID-19 vaccine, which is a different technology but serves the same market as CureVac's vaccine candidates.

Sanofi competes in the vaccine and therapeutic market, working on mRNA vaccines and other technologies that could compete with CureVac's products.

GlaxoSmithKline plc competes in the vaccine space, including collaborations on COVID-19 vaccines and other therapeutic areas that overlap with CureVac's interests.

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. is involved in the development of mRNA vaccines and therapeutics, making it a direct competitor in the same technology space as CureVac.

Translate Bio, now a part of Sanofi, focuses on mRNA technologies for vaccines and therapeutics, directly competing with CureVac in the mRNA space.

About

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Show more...

CEO

Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D.

Employees

764

Country

DE

ISIN

NL0015436031

Listings